Botanix Pharmaceuticals Ltd
ASX:BOT

Watchlist Manager
Botanix Pharmaceuticals Ltd Logo
Botanix Pharmaceuticals Ltd
ASX:BOT
Watchlist
Price: 0.115 AUD -4.17% Market Closed
Market Cap: 226.6m AUD

Intrinsic Value

The intrinsic value of one BOT stock under the Base Case scenario is 0.563 AUD. Compared to the current market price of 0.115 AUD, Botanix Pharmaceuticals Ltd is Undervalued by 80%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BOT Intrinsic Value
0.563 AUD
Undervaluation 80%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Botanix Pharmaceuticals Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about BOT?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BOT valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Botanix Pharmaceuticals Ltd.

Explain Valuation
Compare BOT to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

A delay or failure in Botanix’s clinical trials for its leading synthetic cannabinoid therapies would significantly undermine investor confidence, given that the company’s core revenue potential relies on successful product approvals for conditions like acne and dermatitis.

Highly competitive dermatology and cannabinoid-based therapeutics markets threaten Botanix’s ability to secure sufficient market share upon commercialization, especially as larger pharmaceutical firms introduce rival cannabinoid or transdermal innovations.

The company’s modest cash reserves and reliance on external funding for research and development could introduce substantial dilution risk for shareholders if trials become more expensive or require additional phases.

Bull Theses

Botanix’s proprietary Permetrex technology, designed to enhance the skin penetration of its synthetic cannabinoid formulations, provides a potential competitive advantage in drug delivery and differentiation from other dermatology players.

Early clinical data suggesting efficacy in treating acne and atopic dermatitis positions Botanix to capture significant market share once regulatory approvals are obtained, thanks to the growing demand for more advanced topical solutions.

Management’s focus on strategic partnerships and out-licensing opportunities could accelerate commercialization and mitigate funding risks, leveraging larger pharmaceutical partners’ resources to support late-stage trials and product launches.

Show More Less
How do you feel about BOT?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Botanix Pharmaceuticals Ltd

Current Assets 99.6m
Cash & Short-Term Investments 65m
Receivables 3.2m
Other Current Assets 31.4m
Non-Current Assets 29.5m
PP&E 1.4m
Intangibles 28.1m
Other Non-Current Assets -100
Current Liabilities 24.9m
Accounts Payable 11.7m
Accrued Liabilities 1.9m
Other Current Liabilities 11.3m
Non-Current Liabilities 22.9m
Long-Term Debt 22.9m
Efficiency

Free Cash Flow Analysis
Botanix Pharmaceuticals Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Botanix Pharmaceuticals Ltd

Revenue
5.8m AUD
Cost of Revenue
-3.6m AUD
Gross Profit
2.1m AUD
Operating Expenses
-90.2m AUD
Operating Income
-88m AUD
Other Expenses
1.6m AUD
Net Income
-86.4m AUD
Fundamental Scores

BOT Profitability Score
Profitability Due Diligence

Botanix Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

23/100
Profitability
Score

Botanix Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

BOT Solvency Score
Solvency Due Diligence

Botanix Pharmaceuticals Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Short-Term Solvency
High Altman Z-Score
Low D/E
89/100
Solvency
Score

Botanix Pharmaceuticals Ltd's solvency score is 89/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BOT Price Targets Summary
Botanix Pharmaceuticals Ltd

There are no price targets for BOT.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BOT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one BOT stock?

The intrinsic value of one BOT stock under the Base Case scenario is 0.563 AUD.

Is BOT stock undervalued or overvalued?

Compared to the current market price of 0.115 AUD, Botanix Pharmaceuticals Ltd is Undervalued by 80%.

Back to Top